Company History

  • June 2015

    China Biologic sold 805,000 shares of common stock from its treasury stock in a follow-on offering, and raised net proceeds of approximately $80.6 million.
  • April 2015

    Guizhou Taibang received a one-time special approval from the CFDA to purchase approximately 143 tonnes of source plasma and plasma paste from Xinjiang Deyuan Bioengineering Co., Ltd., for a total consideration of approximately RMB139 million (approximately US$22.6 million).
  • November 2014

    Shandong Taibang received the approval from the Hebei Provincial Health and Family Planning Commission to build two new plasma collection stations in Hebei Province.
  • October 2014

    Shandong Taibang received manufacturing approval certificate for Human Prothrombin Complex Concentrate ("PCC") from China Food and Drug Administration (“CFDA”).
FirstPage | PreviousPage | NextPage | LastPage CurrentPageIndex:3 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] 
© 2017 China Biologic Products Holdings, Inc. All Rights Reserved.